Comparative Pharmacology
Head-to-head clinical analysis: ELAPRASE versus ELFABRIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELAPRASE versus ELFABRIO.
ELAPRASE vs ELFABRIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Idursulfase is a recombinant form of iduronate-2-sulfatase, the enzyme deficient in Hunter syndrome (MPS II). It hydrolyzes 2-sulfate groups from the terminal iduronate sulfate glycosaminoglycans (GAGs) dermatan sulfate and heparan sulfate, thereby reducing GAG accumulation in tissues.
Recombinant human α-galactosidase A enzyme that hydrolyzes globotriaosylceramide (Gb3) and other glycosphingolipids with terminal α-galactosyl groups, thereby reducing accumulation in tissues.
0.58 mg/kg IV once weekly administered over 1 hour
1 mg/kg intravenously over 2 hours every 2 weeks.
None Documented
None Documented
Terminal half-life: 6.5–8.5 hours (mean 7.5 h) in pediatric patients; supports weekly IV dosing
Terminal elimination half-life approximately 0.5–1 hour; short half-life necessitates twice-weekly intravenous dosing.
Renal: negligible; primarily catabolized via peptide hydrolysis to amino acids, which are reused or excreted
Primarily eliminated via renal excretion as intact protein; minimal biliary/fecal elimination (<1%).
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy